Patient treatment
tumor, death, toxicity, cancer, intercurrent illness
CANCER, TUMOR, EVENT
Lead investigators agreed on the cytotoxic chemotherapies used in the trial, and the health insurance plans covered them, thus study participants incurred no additional medical bills. The regimens and doses tested by the ChemoID drug response assay were the same as the ones that could be chosen by the physicians for patients enrolled in the control arm (Patients received 1 of 14 cytotoxic chemotherapy regimens either chosen by the physician or guided by the ChemoID assay test report (The assay-guided group received the regimen that killed the most cancer stem cells and the bulk of the tumor. The treatment given to subjects in the control group was chosen from the same list of chemotherapies tested by the assay (For patients in the assay-guided group, in the event of unacceptable toxicity or progression, treatment was changed to the next best chemotherapeutic drug or combination based on the ChemoID assay report. In cases in which the assay predicted more than one high-cell kill drug, for patients randomized to the assay-guided arm, the protocol gave the physicians the ability to choose a treatment among the high-cell kill drugs based on the ChemoID assay report that would benefit the patient, considering the patient’s general health status.Bevacizumab is not expected to improve overall survivalIn the absence of treatment delays due to the presence of adverse event(s), treatment continued as specified in the above treatment modality sections or until one of the following criteria was applicable: hospice or patients’ death, intercurrent illness that prevents further administration of treatment, unacceptable adverse event(s), patient decides to withdraw consent for participation in the study, or general or specific changes in the patient’s condition render the patient unacceptable for further treatment in the judgment of the investigator.